Serum Levels of Aryl Hydrocarbon Receptor Plasma Agonist Activity Are Reduced in Patients With NMOSD and Correlate With Disease Activity

By afschroeder • August 6, 2025

Tsaktanis T, Ammon L, Lößlein L, Peter A, Vandrey O, Naumann UJ, Behne M, Cook LJ, Levy M, Yeaman MR, Bennett JL, Rothhammer V; Guthy-Jackson Charitable Foundation CIRCLES Study Group. Serum Levels of Aryl Hydrocarbon Receptor Plasma Agonist Activity Are Reduced in Patients With NMOSD and Correlate With Disease Activity. Neurol Neuroimmunol Neuroinflamm. 2025 Sep;12(5):e200457. doi: 10.1212/NXI.0000000000200457. Epub 2025 Aug 5. PMID: 40763318.

Tags: Harbor UCLA, Infectious Diseases, Publications

Validating the standardised outcomes in nephrology-life participation (SONG-LP) measure in people receiving peritoneal dialysis: Rationale and process

Burnett CT, Jaure A, Hughes A, Ju A, Howell M, Manera K, Cheetham M, Johnson DW, Wilkie M, Loud F, Figueiredo A, Cheung C, Schwartz[...]

Doxorubicin, bleomycin, vinblastine, and dacarbazine for Hodgkin lymphoma: Real-world experience from a Los Angeles County hospital

Chao E, Marshalek JP, Yashar D, Tomassetti S. Doxorubicin, bleomycin, vinblastine, and dacarbazine for Hodgkin lymphoma: Real-world experience from a Los Angeles County hospital. SAGE[...]

Understanding the Determinants of Decision Readiness in Kidney Replacement Therapy: Shared Decision Making, Health Literacy, and Population-Health Strategies

Kalantar-Zadeh K, Zisman-Ilani Y. Understanding the Determinants of Decision Readiness in Kidney Replacement Therapy: Shared Decision Making, Health Literacy, and Population-Health Strategies. Clin J Am[...]